All In Biotech

Free tool

FAERS Monitor: Symfi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022142 or its brand name (Symfi, Efavirenz, Lamivudine, Tenofovir Disoproxil Fumarate). Reports on generic versions are filed under their own applications.

Reports

30

Serious

21

70% of reports

Hospitalization

3

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anhedonia8
  • anxiety8
  • emotional distress8
  • pain8
  • bone density decreased6
  • foetal exposure during pregnancy4
  • headache4
  • osteoporosis4
  • renal failure4
  • back pain3
  • bone demineralisation3
  • chronic kidney disease3
  • gait disturbance3
  • acute kidney injury2
  • dizziness2

Reports by year received

View as table
YearReports
20181
20198
20206
20216
20221
20235
20241
20252

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,129 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bone demineralisationSignal31993.8680.34,137
anhedoniaSignal8213.5117.91,488
bone density decreasedSignal6134.365.6667
osteoporosisSignal468.227.4202
emotional distressSignal846.325.6313
foetal exposure during pregnancySignal434.513.999
chronic kidney diseaseSignal327.79.553
renal failureSignal421.18.558
anxietySignal819.710.9126
gait disturbanceSignal311.03.818
acute kidney injury29.22.48
painSignal89.15.052
back painSignal39.13.114
headacheSignal44.51.88
dizziness22.80.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.